The effects of quinapril and atorvastatin on the responsiveness to sildenafil in men with erectile dysfunction

Alan J. Bank, Aaron S. Kelly, Daniel R. Kaiser, William W. Crawford, Benjamin Waxman, Douglas A. Schow, Kevin L. Billups

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Phosphodiesterase-5 (PDE-5) inhibitors are an effective therapy for the majority of men with erectile dysfunction (ED). However, many men with ED still report a suboptimal or partial response even after an adequate trial of oral PDE-5 therapy. Since ED is associated with impaired vascular function and both atorvastatin and quinapril have been previously shown to improve vascular function, we examined the effects of adjunctive treatment with these medications in men with vasculogenic ED who were suboptimal responders to 100 mg of sildenafil. Men with ED and suboptimal response to sildenafil were randomly assigned to 3 months of treatment with atorvastatin 40 mg (n = 12), quinapril 10 mg (n = 10), or placebo (n = 13), along with continued adjunctive sildenafil use. Measured variables included: International Index of Erectile Function (IIEF) questionnaire, brachial artery flow-mediated dilation (FMD), endothelium-independent dilation (EID) via nitroglycerin, penile Doppler blood flow, blood pressure (BP), lipids, and C-reactive protein (CRP). Compared to placebo, quinapril (p < 0.01) significantly improved symptoms of ED as measured by the IIEF-5 questionnaire. There was a trend toward a significant improvement in IIEF-5 with atorvastatin. Similarly, quinapril significantly improved the IIEF ED Domain (p < 0.05). Other peripheral and penile vascular parameters were unchanged with drug therapy as compared to placebo. In conclusion, treatment with quinapril, in combination with sildenafil, improved ED in men with suboptimal response to sildenafil alone. Atorvastatin demonstrated a trend toward improved ED in this group.

Original languageEnglish (US)
Pages (from-to)251-257
Number of pages7
JournalVascular Medicine
Volume11
Issue number4
DOIs
StatePublished - Dec 1 2006

Fingerprint

Erectile Dysfunction
Blood Vessels
Placebos
Dilatation
Type 5 Cyclic Nucleotide Phosphodiesterases
Therapeutics
Atorvastatin Calcium
quinapril
Sildenafil Citrate
Phosphodiesterase 5 Inhibitors
Brachial Artery
Nitroglycerin
C-Reactive Protein
Endothelium
Blood Pressure
Lipids
Drug Therapy

Keywords

  • Atorvastatin
  • Erectile dysfunction
  • Quinapril

Cite this

The effects of quinapril and atorvastatin on the responsiveness to sildenafil in men with erectile dysfunction. / Bank, Alan J.; Kelly, Aaron S.; Kaiser, Daniel R.; Crawford, William W.; Waxman, Benjamin; Schow, Douglas A.; Billups, Kevin L.

In: Vascular Medicine, Vol. 11, No. 4, 01.12.2006, p. 251-257.

Research output: Contribution to journalArticle

Bank, Alan J. ; Kelly, Aaron S. ; Kaiser, Daniel R. ; Crawford, William W. ; Waxman, Benjamin ; Schow, Douglas A. ; Billups, Kevin L. / The effects of quinapril and atorvastatin on the responsiveness to sildenafil in men with erectile dysfunction. In: Vascular Medicine. 2006 ; Vol. 11, No. 4. pp. 251-257.
@article{668980ca633d4753bedf1b777c75a75f,
title = "The effects of quinapril and atorvastatin on the responsiveness to sildenafil in men with erectile dysfunction",
abstract = "Phosphodiesterase-5 (PDE-5) inhibitors are an effective therapy for the majority of men with erectile dysfunction (ED). However, many men with ED still report a suboptimal or partial response even after an adequate trial of oral PDE-5 therapy. Since ED is associated with impaired vascular function and both atorvastatin and quinapril have been previously shown to improve vascular function, we examined the effects of adjunctive treatment with these medications in men with vasculogenic ED who were suboptimal responders to 100 mg of sildenafil. Men with ED and suboptimal response to sildenafil were randomly assigned to 3 months of treatment with atorvastatin 40 mg (n = 12), quinapril 10 mg (n = 10), or placebo (n = 13), along with continued adjunctive sildenafil use. Measured variables included: International Index of Erectile Function (IIEF) questionnaire, brachial artery flow-mediated dilation (FMD), endothelium-independent dilation (EID) via nitroglycerin, penile Doppler blood flow, blood pressure (BP), lipids, and C-reactive protein (CRP). Compared to placebo, quinapril (p < 0.01) significantly improved symptoms of ED as measured by the IIEF-5 questionnaire. There was a trend toward a significant improvement in IIEF-5 with atorvastatin. Similarly, quinapril significantly improved the IIEF ED Domain (p < 0.05). Other peripheral and penile vascular parameters were unchanged with drug therapy as compared to placebo. In conclusion, treatment with quinapril, in combination with sildenafil, improved ED in men with suboptimal response to sildenafil alone. Atorvastatin demonstrated a trend toward improved ED in this group.",
keywords = "Atorvastatin, Erectile dysfunction, Quinapril",
author = "Bank, {Alan J.} and Kelly, {Aaron S.} and Kaiser, {Daniel R.} and Crawford, {William W.} and Benjamin Waxman and Schow, {Douglas A.} and Billups, {Kevin L.}",
year = "2006",
month = "12",
day = "1",
doi = "10.1177/1358863x06072221",
language = "English (US)",
volume = "11",
pages = "251--257",
journal = "Vascular Medicine (United Kingdom)",
issn = "1358-863X",
publisher = "SAGE Publications Ltd",
number = "4",

}

TY - JOUR

T1 - The effects of quinapril and atorvastatin on the responsiveness to sildenafil in men with erectile dysfunction

AU - Bank, Alan J.

AU - Kelly, Aaron S.

AU - Kaiser, Daniel R.

AU - Crawford, William W.

AU - Waxman, Benjamin

AU - Schow, Douglas A.

AU - Billups, Kevin L.

PY - 2006/12/1

Y1 - 2006/12/1

N2 - Phosphodiesterase-5 (PDE-5) inhibitors are an effective therapy for the majority of men with erectile dysfunction (ED). However, many men with ED still report a suboptimal or partial response even after an adequate trial of oral PDE-5 therapy. Since ED is associated with impaired vascular function and both atorvastatin and quinapril have been previously shown to improve vascular function, we examined the effects of adjunctive treatment with these medications in men with vasculogenic ED who were suboptimal responders to 100 mg of sildenafil. Men with ED and suboptimal response to sildenafil were randomly assigned to 3 months of treatment with atorvastatin 40 mg (n = 12), quinapril 10 mg (n = 10), or placebo (n = 13), along with continued adjunctive sildenafil use. Measured variables included: International Index of Erectile Function (IIEF) questionnaire, brachial artery flow-mediated dilation (FMD), endothelium-independent dilation (EID) via nitroglycerin, penile Doppler blood flow, blood pressure (BP), lipids, and C-reactive protein (CRP). Compared to placebo, quinapril (p < 0.01) significantly improved symptoms of ED as measured by the IIEF-5 questionnaire. There was a trend toward a significant improvement in IIEF-5 with atorvastatin. Similarly, quinapril significantly improved the IIEF ED Domain (p < 0.05). Other peripheral and penile vascular parameters were unchanged with drug therapy as compared to placebo. In conclusion, treatment with quinapril, in combination with sildenafil, improved ED in men with suboptimal response to sildenafil alone. Atorvastatin demonstrated a trend toward improved ED in this group.

AB - Phosphodiesterase-5 (PDE-5) inhibitors are an effective therapy for the majority of men with erectile dysfunction (ED). However, many men with ED still report a suboptimal or partial response even after an adequate trial of oral PDE-5 therapy. Since ED is associated with impaired vascular function and both atorvastatin and quinapril have been previously shown to improve vascular function, we examined the effects of adjunctive treatment with these medications in men with vasculogenic ED who were suboptimal responders to 100 mg of sildenafil. Men with ED and suboptimal response to sildenafil were randomly assigned to 3 months of treatment with atorvastatin 40 mg (n = 12), quinapril 10 mg (n = 10), or placebo (n = 13), along with continued adjunctive sildenafil use. Measured variables included: International Index of Erectile Function (IIEF) questionnaire, brachial artery flow-mediated dilation (FMD), endothelium-independent dilation (EID) via nitroglycerin, penile Doppler blood flow, blood pressure (BP), lipids, and C-reactive protein (CRP). Compared to placebo, quinapril (p < 0.01) significantly improved symptoms of ED as measured by the IIEF-5 questionnaire. There was a trend toward a significant improvement in IIEF-5 with atorvastatin. Similarly, quinapril significantly improved the IIEF ED Domain (p < 0.05). Other peripheral and penile vascular parameters were unchanged with drug therapy as compared to placebo. In conclusion, treatment with quinapril, in combination with sildenafil, improved ED in men with suboptimal response to sildenafil alone. Atorvastatin demonstrated a trend toward improved ED in this group.

KW - Atorvastatin

KW - Erectile dysfunction

KW - Quinapril

UR - http://www.scopus.com/inward/record.url?scp=33947541245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947541245&partnerID=8YFLogxK

U2 - 10.1177/1358863x06072221

DO - 10.1177/1358863x06072221

M3 - Article

C2 - 17390549

AN - SCOPUS:33947541245

VL - 11

SP - 251

EP - 257

JO - Vascular Medicine (United Kingdom)

JF - Vascular Medicine (United Kingdom)

SN - 1358-863X

IS - 4

ER -